<DOC>
	<DOCNO>NCT00337883</DOCNO>
	<brief_summary>This Phase II , open-label , multicenter trial single-agent treatment Tarceva patient histologically confirm GBM first relapse . This study seek estimate objective response rate investigate whether response rate relate EGFR amplification status .</brief_summary>
	<brief_title>A Study Safety Efficacy Tarceva Patients With First Relapse Grade IV Glioma ( Glioblastoma Multiforme )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed informed consent Age &gt; = 18 year Histologically confirm GBM first relapse Disease progression patient follow prior implantation Gliadel ( R ) wafer ( ) ( polifeprosan 20 carmustine implant ) must confirm biopsy . Prior therapy Gliadel ( R ) allow component primary surgery . Patients Gliadel ( R ) implant secondary resection eligible . Radiographic evidence disease progression , assess investigator , magnetic resonance imaging ( MRI ) CT scan Bidimensionally measurable disease minimum measurement 1 cm MRI CT scan perform within 14 day prior study entry Prior radiotherapy Availability tissue allow central confirmation GBM diagnosis ( original slide prefer ) Availability paraffin block slide allow determination EGFR amplification status Recovery toxic effect prior therapy , include 4 week prior cytotoxic agent ( except 6 week prior nitrosoureas , 3 week prior procarbazine administration , 2 week prior vincristine , 3 week irinotecan [ CPT11 ] give weekly schedule ) , 4 week prior investigational agent , 1 week prior noncytotoxic agent ( e.g. , interferon , tamoxifen , thalidomide , 13cisretinoic acid , etc . ) If receive corticosteroid , patient must stable , nonincreasing dose corticosteroid &gt; = 2 week prior baseline MRI scan ECOG performance status 0 1 Life expectancy &gt; 12 week Use effective mean contraception male females childbearing potential Ability comply study followup procedure If decision make end Stage 1 enroll patient tumor know positive EGFR amplification , follow additional inclusion criterion apply : Confirmation diagnosis ; Confirmation positive EGFR amplification status Prior treatment Gleevec ( e.g. , imatinib mesylate ) agent direct EGFR ( e.g. , Iressa ) Prior treatment Gliadel ( R ) follow second ( salvage debulking ) therapy History malignancy within 5 year ( except nonmelanoma skin cancer carcinoma situ cervix ) More one prior chemotherapy regimen ANC &lt; 1500/uL Platelets &lt; 100,000/uL Total bilirubin &gt; 1.6 mg/dL AST/ALT &gt; = 2.5 x upper limit normal ( ULN ) Creatinine &gt; 1.5 x ULN Pregnant nursing female Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior study entry , serious cardiac arrhythmia require medication Major surgical procedure 2 week prior study entry anticipation need major surgical procedure course study Inability take oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>glioma</keyword>
	<keyword>Grade IV glioma</keyword>
</DOC>